We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

0 hedge funds and large institutions have $4K invested in Epizyme, Inc in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 93 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 930 (-93)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

100% less capital invested

Capital invested by funds: $187M → $4K (-$187M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 93

Holders
Holders Change
-93
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
93
Calls
Puts
Net Calls
Net Calls Change

EPZM Hedge Fund Activity: Q3 2022 in Review

0 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2022, worth a combined $4K — down 100% from $187M a quarter earlier.

Sellers outnumbered buyers: 93 funds closed out of EPZM and 0 opened new positions — a net loss of 93 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was RP Management, exiting entirely with an estimated $46.8M sold.

  • 0 institutional investors held Epizyme, Inc (EPZM) as of Q3 2022, down from 93 in Q2 2022.
  • Funds reported $4K of Epizyme, Inc stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Epizyme, Inc positions in Q3 2022 and 93 closed out, a net change of -93 holders.
  • The largest Epizyme, Inc seller in Q3 2022 was RP Management, an estimated $46.8M sold.

Based on aggregated 13F filings for Q3 2022.